Mackenzie Financial
RXRX icon

Mackenzie Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Mackenzie Financial’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,980
Closed -$94.3K – 1708
2025
Q4 		$94.3K Buy
22,980
+1,040
+5% +$5.15K ﹤0.01% 1602
2025
Q3 		$107K Buy
21,940
+5,756
+36% +$30.2K ﹤0.01% 1625
2025
Q2 		$81.9K Buy
16,184
+304
+2% +$1.49K ﹤0.01% 1629
2025
Q1 		$84K Buy
15,880
+760
+5% +$5.54K ﹤0.01% 1601
2024
Q4 		$102K Hold
15,120
– – ﹤0.01% 1631
2024
Q3 		$99.6K Buy
+15,120
New +$108K ﹤0.01% 1484

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mackenzie Financial's RXRX Position: Q1 2026 in Review

Mackenzie Financial sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 22,980 shares — an estimated $94.3K sold.

Mackenzie Financial first reported a position in RXRX in Q3 2024 and held it in 6 quarters. The position peaked at $107K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Mackenzie Financial reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 22,980 Recursion Pharmaceuticals shares in Q1 2026, an estimated $94.3K.
  • Mackenzie Financial first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Mackenzie Financial's Recursion Pharmaceuticals position peaked at $107K in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.